These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 29566560)

  • 1. Overcoming problems of poor drug penetration into bacteria: challenges and strategies for medicinal chemists.
    Benedetto Tiz D; Kikelj D; Zidar N
    Expert Opin Drug Discov; 2018 Jun; 13(6):497-507. PubMed ID: 29566560
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nanomaterials and molecular transporters to overcome the bacterial envelope barrier: Towards advanced delivery of antibiotics.
    Santos RS; Figueiredo C; Azevedo NF; Braeckmans K; De Smedt SC
    Adv Drug Deliv Rev; 2018; 136-137():28-48. PubMed ID: 29248479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Designing drugs that overcome antibacterial resistance: where do we stand and what should we do?
    Penchovsky R; Traykovska M
    Expert Opin Drug Discov; 2015 Jun; 10(6):631-50. PubMed ID: 25981754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modeling the Kinetics of the Permeation of Antibacterial Agents into Growing Bacteria and Its Interplay with Efflux.
    Nichols WW
    Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28717042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The history of the development and changes of quinolone antibacterial agents].
    Takahashi H; Hayakawa I; Akimoto T
    Yakushigaku Zasshi; 2003; 38(2):161-79. PubMed ID: 15143768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Siderophores in Iron Metabolism: From Mechanism to Therapy Potential.
    Wilson BR; Bogdan AR; Miyazawa M; Hashimoto K; Tsuji Y
    Trends Mol Med; 2016 Dec; 22(12):1077-1090. PubMed ID: 27825668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The relationship between target-class and the physicochemical properties of antibacterial drugs.
    Mugumbate G; Overington JP
    Bioorg Med Chem; 2015 Aug; 23(16):5218-24. PubMed ID: 25975639
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design and Discovery of New Antibacterial Agents: Advances, Perspectives, Challenges.
    Jampilek J
    Curr Med Chem; 2018; 25(38):4972-5006. PubMed ID: 28925868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bacterial resistance to antibiotics: active efflux and reduced uptake.
    Kumar A; Schweizer HP
    Adv Drug Deliv Rev; 2005 Jul; 57(10):1486-513. PubMed ID: 15939505
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aminoacyl-tRNA synthetase inhibitors as antimicrobial agents: a patent review from 2006 till present.
    Gadakh B; Van Aerschot A
    Expert Opin Ther Pat; 2012 Dec; 22(12):1453-65. PubMed ID: 23062029
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intracellular concentrations of antibacterial agents and related clinical implications.
    Butts JD
    Clin Pharmacokinet; 1994 Jul; 27(1):63-84. PubMed ID: 7955773
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Computational approaches in efflux pump inhibitors: current status and prospects.
    Rathi E; Kumar A; Kini SG
    Drug Discov Today; 2020 Oct; 25(10):1883-1890. PubMed ID: 32712312
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aminoglycosides versus bacteria--a description of the action, resistance mechanism, and nosocomial battleground.
    Shakil S; Khan R; Zarrilli R; Khan AU
    J Biomed Sci; 2008 Jan; 15(1):5-14. PubMed ID: 17657587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. General platform for systematic quantitative evaluation of small-molecule permeability in bacteria.
    Davis TD; Gerry CJ; Tan DS
    ACS Chem Biol; 2014 Nov; 9(11):2535-44. PubMed ID: 25198656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multitarget ligands in antibacterial research: progress and opportunities.
    East SP; Silver LL
    Expert Opin Drug Discov; 2013 Feb; 8(2):143-56. PubMed ID: 23252414
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Understanding efflux in Gram-negative bacteria: opportunities for drug discovery.
    Schweizer HP
    Expert Opin Drug Discov; 2012 Jul; 7(7):633-42. PubMed ID: 22607346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advances and challenges in bacterial compound accumulation assays for drug discovery.
    Six DA; Krucker T; Leeds JA
    Curr Opin Chem Biol; 2018 Jun; 44():9-15. PubMed ID: 29803973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Strategies for bypassing the membrane barrier in multidrug resistant Gram-negative bacteria.
    Bolla JM; Alibert-Franco S; Handzlik J; Chevalier J; Mahamoud A; Boyer G; Kieć-Kononowicz K; Pagès JM
    FEBS Lett; 2011 Jun; 585(11):1682-90. PubMed ID: 21549704
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Counteracting antibiotic resistance: breaking barriers among antibacterial strategies.
    Baquero F; Coque TM; Cantón R
    Expert Opin Ther Targets; 2014 Aug; 18(8):851-61. PubMed ID: 24881465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Whither antibacterial drug discovery?
    Projan SJ
    Drug Discov Today; 2008 Apr; 13(7-8):279-80. PubMed ID: 18405838
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.